Literature DB >> 10888643

The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate.

L M Mansky1, S Preveral, L Selig, R Benarous, S Benichou.   

Abstract

The Vpr protein of human immunodeficiency virus type 1 (HIV-1) influences the in vivo mutation rate of the virus. Since Vpr interacts with a cellular protein implicated in the DNA repair process, uracil DNA glycosylase (UNG), we have explored the contribution of this interaction to the mutation rate of HIV-1. Single-amino-acid variants of Vpr were characterized for their differential UNG-binding properties and used to trans complement vpr null mutant HIV-1. A striking correlation was established between the abilities of Vpr to interact with UNG and to influence the HIV-1 mutation rate. We demonstrate that Vpr incorporation into virus particles is required to influence the in vivo mutation rate and to mediate virion packaging of the nuclear form of UNG. The recruitment of UNG into virions indicates a mechanism for how Vpr can influence reverse transcription accuracy. Our data suggest that distinct mechanisms evolved in primate and nonprimate lentiviruses to reconcile uracil misincorporation into lentiviral DNA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888643      PMCID: PMC112221          DOI: 10.1128/jvi.74.15.7039-7047.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

Review 1.  Genetic diversity and evolution of retroviruses.

Authors:  J M Coffin
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  Characterization of equine infectious anemia virus dUTPase: growth properties of a dUTPase-deficient mutant.

Authors:  D S Threadgill; W K Steagall; M T Flaherty; F J Fuller; S T Perry; K E Rushlow; S F Le Grice; S L Payne
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

3.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

4.  Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein.

Authors:  L J Zhao; S Mukherjee; O Narayan
Journal:  J Biol Chem       Date:  1994-06-03       Impact factor: 5.157

5.  Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.

Authors:  W Paxton; R I Connor; N R Landau
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.

Authors:  N K Heinzinger; M I Bukrinsky; S A Haggerty; A M Ragland; V Kewalramani; M A Lee; H E Gendelman; L Ratner; M Stevenson; M Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

7.  Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.

Authors:  Y L Lu; P Spearman; L Ratner
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.

Authors:  M E Rogel; L I Wu; M Emerman
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

9.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  79 in total

1.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 2.  Viral mutation rates.

Authors:  Rafael Sanjuán; Miguel R Nebot; Nicola Chirico; Louis M Mansky; Robert Belshaw
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

3.  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Authors:  Ferdinand Roesch; Léa Richard; Réjane Rua; Françoise Porrot; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

Review 4.  Plunder and stowaways: incorporation of cellular proteins by enveloped viruses.

Authors:  Réjean Cantin; Sylvie Méthot; Michel J Tremblay
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.

Authors:  Shari M Kaiser; Michael Emerman
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation.

Authors:  Jinwoo Ahn; Thomas Vu; Zach Novince; Jennifer Guerrero-Santoro; Vesna Rapic-Otrin; Angela M Gronenborn
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

7.  Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle.

Authors:  Kasia Hrecka; Magdalena Gierszewska; Smita Srivastava; Lukasz Kozaczkiewicz; Selene K Swanson; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-03       Impact factor: 11.205

Review 8.  Defining the roles for Vpr in HIV-1-associated neuropathogenesis.

Authors:  Tony James; Michael R Nonnemacher; Brian Wigdahl; Fred C Krebs
Journal:  J Neurovirol       Date:  2016-04-07       Impact factor: 2.643

9.  Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Authors:  Bärbel Schröfelbauer; Qin Yu; Samantha G Zeitlin; Nathaniel R Landau
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 10.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.